IBRX Q1 2022 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14,000-89.9% YoY

Gross Profit

-$5M-38528.6% margin

Operating Income

-$96M-685514.3% margin

Net Income

-$103M-734471.4% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

-96.4%

Cash Flow

Operating Cash Flow

-$75M

Free Cash Flow

-$102M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$390M

Total Liabilities

$727M

Stockholders' Equity

-$336M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14,000	$139,000	-89.9%
Gross Profit	-$5M	$139,000	-3980.6%
Operating Income	-$96M	-$86M	-11.3%
Net Income	-$103M	-$80M	-29.2%